Advanced Accelerator Applications Announces Revised EMA Review Timeline for Lutathera®
September 20, 2016 07:00 ET
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear...
Advanced Accelerator Applications Announces Positive EMA Opinion on Application for SomaKit TOC Kit for Radiopharmaceutical Preparation of Gallium (Ga 68) Edotreotide for Gastroenteropancreatic Neuroendocrine Tumor Detection
September 16, 2016 07:00 ET
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Sept. 16, 2016 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in molecular nuclear...
Advanced Accelerator Applications Announces Two Phase II Studies Evaluating 99MrhAnnexin V-128 Imaging in Cardiovascular and Cardio-Oncology Indications at University of Ottawa Heart Institute and Ottawa Hospital
September 06, 2016 07:00 ET
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or the “Company”), an international specialist in Molecular Nuclear...
Advanced Accelerator Applications Reports 24.4% Sales Growth in the Second Quarter of 2016
August 31, 2016 07:00 ET
|
Advanced Accelerator Applications
Highlights: Sales for the second quarter of 2016 increased 24.4% compared to the second quarter of 2015The U.S. Food and Drug Administration (FDA) granted Priority Review for Lutathera, with a...
Advanced Accelerator Applications Announces First Administration of NETSPOT™ at Holy Name Medical Center
August 03, 2016 07:00 ET
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear...
Advanced Accelerator Applications Announces Clinical Trial Agreement with National Cancer Institute for Study of Lutathera in Patients with Inoperable Pheochromocytoma and Paraganglioma
August 02, 2016 07:00 ET
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear...
Advanced Accelerator Applications Announces Opening of First U.S. Manufacturing Facility; Preparation for Anticipated Lutathera Launch
July 26, 2016 07:00 ET
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, July 26, 2016 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear...
Advanced Accelerator Applications Announces FDA Priority Review for Lutathera
June 27, 2016 07:00 ET
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, June 27, 2016 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear...
Advanced Accelerator Applications Expands U.S. NETSPOT™ Supply Chain with Two Additional Radiopharmacy Networks
June 10, 2016 07:00 ET
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, June 10, 2016 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear...
Cardinal Health to Prepare NETSPOT™ Doses for Advanced Accelerator Applications
June 09, 2016 07:50 ET
|
Advanced Accelerator Applications
SAINT-GENIS-POUILLY, France, June 09, 2016 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear...